Clinical Trials on PI3K Pathway Inhibition in Hong Kong
Total 6 results
-
Novartis PharmaceuticalsCompletedPre-menopausal Breast Cancer | PI3K Pathway InhibitionTaiwan, Hong Kong, Thailand, Korea, Republic of
-
The University of Hong KongRecruitingRecurrent Glioblastoma | Recurrent Glioma | Poly ADP Ribose Polymerase (PARP) Inhibitor | PTEN Gene Inactivation | IDH MutationHong Kong
-
Chinese University of Hong KongRecruitingParkinson Disease | Aging | Dementia Alzheimers | Depression in Old Age | Dementia FrontotemporalHong Kong
-
National Cancer Institute (NCI)CompletedNeurofibromatosis Type 1 | Recurrent Childhood Pilocytic Astrocytoma | Recurrent Childhood Visual Pathway GliomaUnited States, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Ependymoma | Childhood Craniopharyngioma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood Infratentorial Ependymoma | Childhood... and other conditionsUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
TauRx Therapeutics LtdTerminatedAlzheimer's Disease | Behavioral Variant Frontotemporal DementiaKorea, Republic of, United States, Spain, Taiwan, Canada, Belgium, Malaysia, United Kingdom, Australia, Singapore, Croatia, Finland, France, Germany, Netherlands, Romania, Russian Federation